Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in hypertensive patients with stable heart failure.

Next Previous
Trial Profile

A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in hypertensive patients with stable heart failure.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Essential hypertension; Heart failure; Hypertension
  • Focus Adverse reactions; Registrational
  • Acronyms ALOFT; ASPIRE-HIGHER
  • Sponsors Novartis

Most Recent Events

  • 04 Apr 2011 Subanalysis results published in the European Journal of Heart Failure.
  • 16 Mar 2010 Results were presented at the 59th Annual Scientific Session of the American College of Cardiology.
  • 02 Sep 2007 Results have been presented.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top